Enfusion, Inc. (NYSE:ENFN) Receives Consensus Rating of “Reduce” from Brokerages

Enfusion, Inc. (NYSE:ENFN) has earned a consensus rating of “Reduce” from the six research firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $9.33.

ENFN has been the subject of a number of research analyst reports. Bank of America increased their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a report on Wednesday, March 13th. Piper Sandler lifted their price target on shares of Enfusion from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday, December 20th. The Goldman Sachs Group cut shares of Enfusion from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $9.00 to $8.00 in a research report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. cut shares of Enfusion from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $11.00 to $9.00 in a research report on Tuesday, January 30th.

Enfusion Price Performance

Shares of NYSE:ENFN opened at $9.53 on Friday. The stock has a market cap of $1.22 billion, a P/E ratio of 119.14, a P/E/G ratio of 2.80 and a beta of 1.00. The firm has a fifty day moving average price of $8.95 and a 200 day moving average price of $9.10. Enfusion has a 1-year low of $7.37 and a 1-year high of $11.56.

Enfusion (NYSE:ENFN) last released its earnings results on Tuesday, March 12th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 10.30% and a net margin of 3.45%. The firm had revenue of $46.49 million during the quarter, compared to analyst estimates of $45.56 million. Sell-side analysts expect that Enfusion will post 0.07 EPS for the current fiscal year.

Institutional Trading of Enfusion

Several institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. increased its stake in Enfusion by 9.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 12,000 shares of the company’s stock valued at $116,000 after purchasing an additional 1,000 shares during the last quarter. American International Group Inc. lifted its holdings in Enfusion by 10.3% in the 2nd quarter. American International Group Inc. now owns 11,920 shares of the company’s stock valued at $122,000 after acquiring an additional 1,115 shares during the last quarter. Amalgamated Bank lifted its holdings in Enfusion by 33.7% in the 3rd quarter. Amalgamated Bank now owns 5,230 shares of the company’s stock valued at $47,000 after acquiring an additional 1,317 shares during the last quarter. Citigroup Inc. lifted its holdings in Enfusion by 24.2% in the 1st quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock valued at $91,000 after acquiring an additional 1,390 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Enfusion by 2.1% in the 3rd quarter. Nuveen Asset Management LLC now owns 69,155 shares of the company’s stock valued at $854,000 after acquiring an additional 1,395 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.